Newsfeeds - Spark Newswire

1 minute read

Kite and Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-ddBCMA In Multiple Myeloma

January 30, 10:07 AM

Kite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc. (NASDAQ:ACLX), today announced the closing of the companies' previously announced global strategic collaboration to co-develop and co-commercialize

ACLX

5 minute read

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

December 19, 2:38 PM

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

ACLX

1 minute read

B of A Securities Reinstates Buy on Arcellx, Announces $37 Price Target

By Benzinga Newsdesk

December 13, 9:48 AM

B of A Securities analyst Jason Gerberry reinstates Arcellx (NASDAQ:ACLX) with a Buy and announces $37 price target.

ACLX

3 minute read

Dow Tumbles 100 Points; Silver Rises Over 2%

By Lisa Levin

December 9, 3:44 PM

U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday

ACLX

4 minute read

Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

December 9, 2:48 PM

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.

ACER

3 minute read

US Stocks Edge Lower; Producer Prices Increase Higher Than Expected

By Lisa Levin

December 9, 10:59 AM

U.S. stocks traded slightly lower this morning following the release of PPI data

ACLX

1 minute read

Gilead’s Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate

By Vandana Singh

December 9, 10:42 AM

Kite, a Gilead Sciences Inc company (NASDAQ:GILD), announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc’s (NASDAQ:ACLX) lead late-stage product candidate, CART-ddBCMA,…

ACLX